Medicover stock
Price history
+12.50% over the period1 year: from kr 228.00 (November 20, 2025) to kr 256.50 (November 20, 2026), +12.50%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | kr 256.50 |
| October 30, 2026 | kr 283.50 |
| September 30, 2026 | kr 260.00 |
| August 31, 2026 | kr 242.50 |
| July 31, 2026 | kr 225.50 |
| June 30, 2026 | kr 230.00 |
| May 29, 2026 | kr 209.00 |
| April 30, 2026 | kr 207.50 |
| March 31, 2026 | kr 188.20 |
| February 27, 2026 | kr 217.50 |
| January 30, 2026 | kr 202.50 |
| December 30, 2025 | kr 220.50 |
| November 28, 2025 | kr 235.50 |
| November 20, 2025 | kr 228.00 |
At a glance
The company
Provides healthcare and diagnostic services including outpatient/inpatient care, dental care, mental health, orthopedics, hospital care and laboratory diagnostics
Latest results
Quarter to September 30, 2026 · EPS €0.16 (estimate €0.17)
TickerLandia's take on Medicover
- Pricier than similar companies: trailing 12-month P/E 38 vs 22 (+72%) in a group of 10.
- Strong point: Growth (71/100 in its group). Weak point: Financial strength (15/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−9.84% from the 52-week high
Analysts · 7 analysts
Average targetkr 287.61+12.13% vs. price
Buy 5 · Hold 2 · Sell 0 · Buy
TickerLandia Fingerprint: Medicover
Compared with similar companies: very high price and very low financial strength.
Financials and price compared with 19 companies in the medical care facilities industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricevery high92
How much it costs relative to what it produces.
Metric Value Position in group Price/sales 15.7 97 P/E (trailing 12 months) 38.3 75 EV/EBITDA 140.3 97 Price/book 72.2 97 Profitabilitylow22
How much it earns on revenue and capital.
Metric Value Position in group ROA 4.8% 29 ROE 15.8% 47 Gross margin 23.5% 13 Operating margin 7.4% 8 Net margin 3.7% 13 Earnings stabilitylow33
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 3.4% 8 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 58 Growthhigh71
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +16.34% 76 Revenue growth (year over year) +6.00% 50 Earnings growth (year over year) +33.80% 87 Financial strengthvery low15
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage 2.45 18 Current ratio 0.75 13 Net debt/EBITDAcounts in reverse: lower means more financial strength 5.27 13 Debt/equitycounts in reverse: lower means more financial strength 2.26 14 Dividendaverage42
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 6 years 33 Payout ratio 32.5% 44 Dividend yield 0.8% 50 Market momentumstrong71
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +12.50% 56 Distance from 200-day average +12.96% 85 Risklow32
How much the price swings.
Metric Value Position in group Volatility (60 days) 20.4% 21 Maximum drawdown (12 months) 22.6% 43
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Medicover is pricier than similar companies
Medicover's P/E (trailing 12 months): 38.3, +72% against the median of a group of 10 similar companies (22.3).
Compared with 10 similar companies
| Metric | Medicover | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 38.3 | Middle | |
| Operating margin | 7.4% | Low | |
| ROE | 15.8% | Middle | |
| Debt/equity | 2.26 | High | |
| Price/book | 72.2 | High |
Grey band: the middle half of the group; tick: the median; dot: Medicover. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€570.8M
Latest quarter · Q3 2026
Net income
€25.7M
Latest quarter · Q3 2026
Quarterly net margin
4.5%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- kr 38.98B
- P/E
- 38.3
- EPS
- kr 6.70
- Volume
- 36.94K
- Daily trading
- €1.79M
- Dividend yield
- 0.85%
- Last ex-dividend on April 30, 2026
How Medicover is changing
All resultsRevenue grew 19.0% a year on average over the last 5 years
Operating margin rose from 4.5% to 6.6%
Shares outstanding up 6.5% in 5 years
Returns
Medicover returns with dividends
kr 1,000 invested in Medicover 5 years ago, on November 22, 2021, would be worth kr 928 today with dividends reinvested: −7.22% in total, −1.49% per year. On price alone it would be kr 891 (−10.94%).
| Period | Medicover | kr 1,000 becomes |
|---|---|---|
| 1 month | −3.57% | kr 964 |
| 6 months | +19.86% | kr 1,199 |
| Year to date | +16.33% | kr 1,163 |
| 1 year | +13.68% | kr 1,137 |
| 3 years | +81.44% | kr 1,814 |
| 5 years | −7.22% | kr 928 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
Medicover: technical analysis
Medicover shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 30.7% below its all-time closing high (kr 370.00, December 30, 2021).
- Trend
- No clear trend
- RSI (14 sessions)
- 37
- Between 30 and 70
- vs 200-session average
- +12.96%
Support and resistance
Price areas where Medicover has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistancekr 259.25+1.07%2 touches, last on November 6, 2026
- Last pricekr 256.50
- Supportkr 249.75−2.63%2 touches, last on September 29, 2026
- Supportkr 231.50−9.75%2 touches, last on September 11, 2026
- Supportkr 223.67−12.80%3 touches, last on February 23, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 20.4%
- Largest fall in the last year
- −22.63%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Medicover: seasonality
Average monthly price change over 10 years
Over the last 10 years, the strongest month for Medicover has been April: +11.07% on average, positive in 7 years out of 9. The weakest has been March: −7.95% on average, positive in 1 years out of 9. November, the current month, has been positive in 5 years out of 9 (+5.42% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +1.92% | −2.32% | 4 of 9 |
| February | +1.13% | +4.16% | 6 of 9 |
| March | −7.95% | −9.00% | 1 of 9 |
| April | +11.07% | +10.32% | 7 of 9 |
| May | +3.22% | +0.72% | 6 of 9 |
| June | −0.42% | +0.76% | 5 of 10 |
| July | +3.58% | +1.83% | 6 of 10 |
| August | −1.20% | −1.20% | 3 of 10 |
| September | −0.37% | −1.96% | 4 of 10 |
| October | +2.16% | +3.24% | 6 of 10 |
| November | +5.42% | +9.87% | 5 of 9 |
| December | +4.80% | +3.88% | 5 of 9 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Medicover and its competitors
Dental care, outpatient clinics, mental health care and diagnostic laboratory tests are the services people most often associate with Medicover. The group provides healthcare and diagnostic services in Poland, Sweden and other markets. Its Healthcare Services segment covers outpatient and inpatient care, hospital care, orthopedics, preventive plans, sports and wellness, and benefit cards, while its Diagnostic Services segment covers tests such as microbiology, human genetics, haematology and histopathology. Its clients are corporate customers, individuals and public sector bodies.
- Headquarters
- Stockholm, Sweden
- Employees
- 49,000
- Founded
- 1995
- Chief executive
- John Stubbington
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| MedicoverMCOV.B | $3.82B | 7.4% | 38.3 | +19.86% |
| Fresenius Medical CareFME | $10.72B | 10.1% | 12.3 | −2.36% |
| Spire Healthcare GroupSPI | $1.3B | 7.6% | — | +12.90% |
| TerveystaloTTALO | $830.61M | 8.9% | 13.0 | −27.00% |
| FreseniusFRE | $31.8B | 9.9% | 18.4 | +27.91% |
| Mouwasat Medical Services4002 | $3.16B | 25.8% | 13.5 | −14.59% |
Same industry or related industries, similar size. Compare Medicover with its competitors · Full profile
